Stockscreener 앱 받기
8.76
0.45%
-0.04
전일 마감가:
$8.80
열려 있는:
$8.8
하루 거래량:
60,302
Relative Volume:
0.76
시가총액:
$232.07M
수익:
-
순이익/손실:
$-22.38M
주가수익비율:
-6.2128
EPS:
-1.41
순현금흐름:
$-15.54M
1주 성능:
-1.46%
1개월 성능:
+5.42%
6개월 성능:
+37.52%
1년 성능:
+26.04%
1일 변동 폭
$8.69
$9.23
1주일 범위
$8.12
$9.23
52주 변동 폭
$5.55
$11.52
Nuvectis Pharma Inc Stock (NVCT) Company Profile
명칭
Nuvectis Pharma Inc
전화
360-837-7232
주소
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
8.76 | 233.13M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Maxim Group | Buy |
| 2025-03-17 | 개시 | Laidlaw | Buy |
| 2022-07-13 | 개시 | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Nuvectis Pharma FY2026 EPS Estimate Cut by HC Wainwright - Defense World
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB) - The Globe and Mail
HC Wainwright Forecasts Weaker Earnings for Nuvectis Pharma - MarketBeat
HC Wainwright Comments on Nuvectis Pharma Q1 Earnings - Defense World
Can Nuvectis Pharma Inc. stock hit record highs againMarket Sentiment Review & High Yield Equity Trading Tips - mfd.ru
HC Wainwright Predicts Nuvectis Pharma Q1 Earnings - MarketBeat
Nuvectis Pharma, Inc. reports 2025 financial results and business highlights - marketscreener.com
Nuvectis Pharma, Inc. SEC 10-K Report - TradingView
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights - The Manila Times
Risk Analysis: Does Nuvectis Pharma Inc. have a competitive edgeEarnings Miss & Precise Entry and Exit Recommendations - baoquankhu1.vn
Investment Report: Is Nuvectis Pharma Inc attractive for institutional investorsJuly 2025 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
(NVCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8%Should You Buy? - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy? - Defense World
Is Nuvectis Pharma Inc. stock a buy on dipsQuarterly Growth Report & Real-Time Volume Spike Alerts - bollywoodhelpline.com
Will Nuvectis Pharma Inc. stock outperform value stocksInsider Selling & Precise Trade Entry Recommendations - bollywoodhelpline.com
Investment Report: Will Nuvectis Pharma Inc outperform tech stocksGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Energy Moves: Is Nuvectis Pharma Inc stock a good pick for beginnersRisk Management & Low Drawdown Trading Techniques - baoquankhu1.vn
Take Profit: Can Nuvectis Pharma Inc maintain its current growth rateBreakout Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Spikes: Can Nuvectis Pharma Inc stock beat analyst upgradesJuly 2025 Recap & Real-Time Volume Spike Alerts - moha.gov.vn
What Wall Street predicts for Nuvectis Pharma Inc. stock price2025 Major Catalysts & Advanced Swing Trade Entry Plans - Улправда
We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st
Will Nuvectis Pharma Inc. stock benefit from commodity pricesSmall Cap Stock Opportunities & Grow Smarter With Pro-Level Research - Улправда
Why (NVCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - MSN
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5%Here's Why - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why - Defense World
(NVCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Is Nuvectis Pharma Inc a good long term investmentEx-Dividend Date Alerts & High Return Trading Strategies - earlytimes.in
Why Nuvectis Pharma Inc. stock remains on buy listsFed Meeting & Growth Focused Stock Reports - Улправда
How rising interest rates impact Nuvectis Pharma Inc. stockEarnings Growth Summary & Verified Swing Trading Watchlists - DonanımHaber
Can Nuvectis Pharma Inc. stock beat analyst upgrades2025 Earnings Impact & Daily Growth Stock Investment Tips - DonanımHaber
Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Sentiment Report & Entry and Exit Point Strategies - DonanımHaber
Will Nuvectis Pharma Inc. stock maintain dividend yield2025 Risk Factors & Weekly Stock Breakout Alerts - DonanımHaber
Weekly Recap: Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Trend Summary & Capital Efficient Trade Techniques - bolumsonucanavari.com
Nuvectis Pharma announces initiation of Phase 1b study of NXP900 - MSN
Nuvectis Begins Phase 1b Study to Address Drug Resistance in Lung Cancer - socialunderground.co
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib By Investing.com - Investing.com Nigeria
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies - TipRanks
Nuvectis Pharma Starts Phase 1b Study With Osimertinib for Non-Small Cell Lung Cancer - marketscreener.com
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib - Investing.com
Nuvectis Pharma announces the initiation of the phase 1b study of NXP900 in combination with osimertinib in patients with NSCLC - marketscreener.com
Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients - Quiver Quantitative
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC - Sahm
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
Nuvectis Pharma Shares Gain Momentum on Analyst Backing and Clinical Progress - AD HOC NEWS
Nuvectis Pharma (NVCT) Stock Analysis Report | Financials & Insights - Benzinga
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Yahoo Finance
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st
Technical Reactions to NVCT Trends in Macro Strategies - news.stocktradersdaily.com
Nuvectis Pharma Inc (NVCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):